Goodbye Columbus! New NRDOs forego discovery

Companies that eschew drug discovery in favor of in-licensing have captured a lot of attention and investment over the past few years. But are these young companies really chasing a sustainable business model?

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Deal terms are rising over time for all stages of drug development.

Bob Crimi


  1. 1

    Sampaio, E.P. et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173, 699–703 (1991).

  2. 2

    Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565–1571 (1999).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading